

## IDENTIFYING GLOBAL ISSUES

**Diabetic Retinopathy:** Diabetic retinopathy is a complication caused by an existing history of diabetes/diabetic symptoms that can slowly deteriorate a person's vision and can even lead to partial blindness. Often this diabetic complication can be treated by timely management of the condition and/or modern laser eye treatments/surgery. However, this treatment of diabetic retinopathy is often expensive and can have side effects. Its effects seemingly take on worse results. These severe cases are often seen in developing nations where general access to medical testing is bleak with most patients unsure of their severity until physical implications become apparent. In fact, 79% of the adults with diabetes reside within low-to-middle income nations and serve a major risk of joining the estimated 93 million people worldwide suffering from diabetic retinopathy. Without significant medical testing, which can often prove expensive, and local ophthalmologists, this population is the most at risk of developing blindness and suffering the consequences of this complication.




**Water Pollution:** This problem catches our attention because 2.4 billion people suffer the problem of inadequate sanitation worldwide. This puts them at risk of many deadly diseases such as cholera, typhoid fever, etc. Inventing something that could help fix this would be beneficial to third world countries that don't receive the clean water we do.



**Red Tide:** This problem catches our attention because it comes and goes in Florida and figuring out a permanent end would benefit both humans and our wildlife.

## WHY WE CHOSE THIS PROBLEM?

Diabetic retinopathy is a complication caused by an existing history of diabetes/diabetic symptoms that can slowly deteriorate a person's vision and can even lead to partial blindness. Often this diabetic complication can be treated by timely management of the condition and modern laser eye treatments. However, this treatment of diabetic retinopathy cannot completely cure the disease and, when left untreated, its effects will worsen. These severe cases are often seen in developing nations where general access to medical testing is bleak with most patients unsure of their severity until physical implications become apparent. In fact, 79% of the adults with diabetes reside within low-to-middle income nations and serve a major risk of joining the estimated 93 million people worldwide suffering from diabetic retinopathy. Without significant medical testing, which can often prove expensive, and local ophthalmologists, this population is the most at risk of developing blindness and suffering the consequences of vision impairment. In this sense, the recent development of low-cost neural networks as a means of detecting early stages of diabetic retinopathy has become a much-needed solution to centuries of unknown suffering as a result of this complication. However, such solutions must be affordable/accessible as well as accurate in their results. This is the basis for this study and the reason for such urgency when it comes to developing solutions.



## HOW THE IDEA CAME TO US?

The idea for creating a low-cost retinal imaging utility for detecting the severity of diabetic retinopathy resulted from a primary experiment we conducted in regards to neural network sampling of DR retinal images. During our research within this previous extensive study, we noted the lack of available resources provided to DR on the low-end and that the accessibility of these retinal tests was a primary factor in the abundance of untreated/preventable cases. With this knowledge of a potentially life-changing niche in the market, we knew we had to act upon this issue. Within a few weeks, we had incorporated our backbone of research and our knowledge into a functioning/open environment for innovation.

## BUSINESS PLAN

**Outline:**  
The product for sale would be the VisionBound device, consisting of Raspberry Pi Zero W, a 30D lens, Raspberry Pi 12 MP HQ Camera, a 2465 Adafruit PowerBoost 1000C Rev B, a Adafruit ST25DV16K I2C RFID EEPROM Breakout, a lithium ion polymer battery (3.7v 2500mAh), a USB-C cable, and an outer shell casing.  
**Intended Audience:**  
The intended audience would be medical centers, global non-profits, and medical research institutions wishing to detect diabetic retinopathy as millions of people across the globe suffer vision complications as a result of diabetic retinopathy, attributed mostly to the lack of appropriate testing.  
**A VisionBound device would diagnose a patient by severity of diabetic retinopathy in order to combat vision complications early on.**

### Profit

- A VisionBound device begins at \$250.00.
- Any medical centers willing to share results and patients' overall feelings, as long as patients willingly consent too, would receive a 5% discount on each additional VisionBound device.
- Medical centers, such as Gulf Coast Medical Center, and global non-profits, such as the World Health Organization, would be an ideal source for profit and exposure.

### Prosperity and Challenge

- This project will succeed when access to diabetic retinopathy testing is increased and the vision complications that form from diabetic retinopathy diminish.
- The inventors would like to make an environmental profit as much as a monetary one by keeping a compact form factor, resulting in less materials being used.
- A challenge underdeveloped medical centers might face is affording a VisionBound device but the inventors will partner up with non-profit organizations, such as Direct Relief, and decrease the price as requested.

### Licensing

The benefits to licensing our idea are that it provides a greater chance to reach patients and the medical market. For example, medical centers would greatly benefit from VisionBound as the use of it would lead to increased diabetic retinopathy testing, thus increasing the number of patients who need to be treated for diabetic retinopathy. This epidemic is amplified by the fact of appropriate testing as to the severity of DR. Licensing our idea would prompt change within this field because it would enable licensed partners to expand upon our own packaging, advertising, sales, insurance, transportation, and storage of the VisionBound utility. While Visionbound is relatively low-cost compared to the test methods current in the market, we would still coordinate with our licensees to ensure affordable prices for underdeveloped markets/areas.

## SALES PITCH

Are your patients' health your top priority? Millions of people across the globe suffer vision complications as a result of diabetic retinopathy, mostly due to the lack of appropriate testing. When left untreated, diabetic retinopathy seemingly takes on worse results. These severe cases are often seen in developing nations where general access to medical testing is bleak with most patients unsure of their severity until physical implications become apparent. In fact, 79% of the adults with diabetes reside within low-to-middle income nations and serve a major risk of joining the estimated 93 million people worldwide suffering from diabetic retinopathy. Without significant medical testing, which can often prove expensive, this population is the most at risk of developing blindness and suffering the consequences of vision impairment. This is where our product comes in: the Visionbound device diagnoses a patient by severity of diabetic retinopathy in order to combat vision complications early on. With our unique design, this product can increase access to diabetic retinopathy testing. At the affordable price of \$250.00, this product will not just modernize the market of point-of-care utilities, but it'll also offer a lasting improvement to people all across the globe.

All graphs and figures above were created by the inventors

# VISIONbound™

Aum Dhruv & Nicholas Harty | NI-HM-171 | Fort Myers High School  
Grade 11 | Fort Myers, FL | Health and Medical | Patent Under Counsel

## BRIDGING THE GAP BETWEEN TECHNOLOGY AND PREVENTABLE RETINAL DISEASES




## PRELIMINARY RESEARCH

### Convolutional Neural Network (CNN) Research:

The first of these recognition methods, the convolutional neural network algorithm, works by pooling various elements of a training sample into feature maps, and then undergoing a convolution process that exponentially decreases the size of the image into basic constraints. Its ability to break down the various prominent features of media allows it to function as an essential component in the classification of bitmaps, moving graphics, and audio samples. In this study, the description of this algorithm will focus on image classification as it relates to the entirety of the neural network's function and its ability to discern the components of an image and contrast the features of two corresponding images when dealing with necessary classification. This system of assigning importance to various features of an image is described as the CNN. Initially, this system breaks down the image into several layers. The first Layer is the Green Layer, the Blue Layer, and in some cases, the Alpha/Intensity Layer. This breakdown is measured by a pixel, in a standard training image, being composed of three RGB values between 0-255 in intensity and an alpha value between 0-1 in opacity. From this point of divergence, the algorithm begins dissecting the image for features through a series of four scientific steps defined by most computer analysts as essential "layers": These layers are composed of the Convolution Layer, the Pooling Layer, the Rectified Linear Unit (ReLU) Layer, and the Fully Connected Layer.

The image above was created by the researchers



### K-Nearest Neighbors (KNN) Research:

The second of these algorithms, the k-nearest neighbors algorithm, is trained on various groups of images in order to classify a given unknown image. A simple implementation allows it to function as an essential component in image recognition, video recognition, and speech recognition. KNN is used for classification and regression. In this study, the description of this algorithm will focus on image classification as it relates to the entirety of the neural network's functionality. This process uses a predetermined number of "n" nearest neighbors to determine the class of a new sample based on the class of the samples that a model generates. This can also be done by developing a rudimentary algorithm to break down images via kernelling or random pixel sampling, into the necessary logits. To elaborate, for each group of images, a matrix is created of shape [n, 1000], in which "n" is the number of samples per group. MobileNet deploys new images into logits, which are then normalized to unit length.


## SUMMARY OF INVENTION & MATERIALS

The final configuration of our product, VisionBound, includes a 30D lens, at a distance of 3cm from the pupil, that is paired with a 12MP Pi High-Quality Camera that interfaces with the microcontroller (Raspberry Pi Zero W). In addition, this design also allows for a wide range of customization via its available snap-in ports on the bottom and side. These customized utilities can interface with the product via its standard USB-C port that also acts as a power and charging port. To complete the design, we also utilized a battery to power the device for mobile consumption. On the physical elements of the product, we utilized a tailored KNN algorithm to discern between that sample's particular stage of DR. Once a conclusion is determined, the testing results are exported via a dynamic NFC transmitter (ST25DV16K) placed under the charging port on the product. This result technology allows users to hover their phones over the labeled NFC area and receive their trial results over the web. This system of exportation was primarily chosen to reduce the cost of using traditional medical records and to provide a truly modern/accessible experience.

### Materials:

Raspberry Pi Zero W	30D Lens (oDocs Optics)	Raspberry Pi High Quality HQ Camera - 12MP	2465 Adafruit PowerBoost 1000C Rev B
Adafruit ST25DV16K I2C RFID EEPROM Breakout	Lithium Ion Polymer Battery - 3.7v 2500mAh	USB-C Charging Cable	Outer Shell Casing / Internal Structure PLA

## OUTER/INNER PLA CONSTRAINT DRAWING



All drawings above were created by the inventors

## ITERATIONS OF DESIGN

### Iterations:

#### Title: Initial/Concept housing unit for the lens/camera configuration.

- Developed in reference to previous research as to particular focal length with studying undilated retina.
- Proved effective as an initial housing concept but lacked the proper constraints to be efficiently manufactured.
- Further models/concepts would be needed in order to ensure efficiency in function and ease-of-use within consumer design.

#### Title: Updated leg design for housing the pipeline for the camera-lens unit.

- Improves upon the previous design by componentizing the entire design of the pipeline.
- By dividing the pipeline into four beams, it allows for lesser fidelity/structural elements when 3D printing. This helps with the ease of creation within the design and lowers the production cost of our prototype.

#### Title: Assembled four-beam housing pipeline for the camera-lens unit.

- The overall design, within this process, was lengthened to provide for updated data (from the lens manufacturer - odocs Optics) regarding optimal focal length.

#### Title: Assembled four-beam housing pipeline for the camera-lens unit with formal holes sanctioned for electronic components.

- The assembled design was modified to provide for formal nut-and-screw holes (dimensions labeled on the PLA drawing) for the following electronic components:

- Raspberry Pi Zero W
- 2465 Adafruit PowerBoost 1000C Rev B
- Raspberry Pi High Quality HQ Camera - 12MP


#### Title: Assembled final product with the outer casing.

- Outer casing and appropriate vents are provided to the rigid four-beam design.
- Outer screw holes for the 30D lens are provided at the front end of the product. This allows for easy adjustment for everyday use and replacement access for damaged lenses.
- An outer IO port section allows easy access to USB-C charging/data transmission and NFC transmission of wireless medical records (Medibound).

#### Title: Assembled final product with the outer casing.

- Screw holes added to the outside of the outer casing for customization. These were added to increase the overall applications of this product in the field.
- These customization features were added in order to maintain longevity throughout our product's life cycle and develop a product family (first and third party) around this utility.

### C.A.D. Representation:



All drawings above were created by the inventors

## INTERPRETATION OF SCIENTIFIC TRIALS

### Results:

To measure the accuracy of the CNN and KNN algorithms, mean and buffered accuracy was calculated for each training sample size. For both algorithms, the mean accuracy (%) was the average of all 50 trials (10 per DR severity). The buffered accuracy (%) provides 1-sigma error bars to either either end of the mean output resulting in an amplified marker of the mean accuracy. In a training sample size of 125 retinal images (ranging in severity), the CNN algorithm resulted in a mean accuracy of 19.36% and a buffered accuracy of 4.02%. In a training sample size of 500 retinal images, the CNN algorithm resulted in a mean accuracy of 25.60% and a buffered accuracy of 5.00%. In a training sample size of 1250 retinal images, the CNN algorithm resulted in a mean accuracy of 20.08% and a buffered accuracy of 5.20%, while the KNN algorithm resulted in a mean accuracy of 20.80% and a buffered accuracy of 5.40%. In a training sample size of 375 retinal images, the CNN algorithm resulted in a mean accuracy of 54.05%, while the KNN algorithm resulted in a mean accuracy of 22.88% and a buffered accuracy of 5.45%. In a training sample size of 500 retinal images, the CNN algorithm resulted in a mean accuracy of 54.56%, while the KNN algorithm resulted in a mean accuracy of 25.60% and a buffered accuracy of 5.44%. In a training sample size of 1000 retinal images, the CNN algorithm resulted in a mean accuracy of 24.68% and a buffered accuracy of 5.50%. In a training sample size of 1500 retinal images, the CNN algorithm resulted in a mean accuracy of 29.00% and a buffered accuracy of 5.60%. In a training sample size of 2000 retinal images, the CNN algorithm resulted in a mean accuracy of 30.64% and a buffered accuracy of 6.20%, while the KNN algorithm resulted in a mean accuracy of 25.20% and a buffered accuracy of 5.62%. In a training sample size of 2500 retinal images, the CNN algorithm resulted in a mean accuracy of 32.16% and a buffered accuracy of 6.33%, while the KNN algorithm resulted in a mean accuracy of 26.44% and a buffered accuracy of 5.70%.

### Trends:


In both algorithms, there was a general increase in accuracy as the training sample size increased. In the CNN algorithm, this increase was steeper compared to the KNN algorithm. This trend can be noted in the slope of the provided line graphs. Due to this, the radar graphs and bar graphs highlighted individual upward trends in each category of diabetic retinopathy by increasing sample size. From the line graphs, the pattern of CNN's spike is evident as the CNN mean accuracy line makes a sharp increase at around 375 samples and in doing so, surpasses the mean accuracy of KNN.

### Significance:

When presented with training sample sizes of 125 and 250 retinal images, KNN was more accurate, which could justify its use over CNN in lower sample sizes. However, in training sample sizes of n>375 and above, CNN was more accurate, which could justify its use over KNN in higher sample sizes. This supported the investigators' hypothesis since the CNN algorithm produced a greater average accuracy across higher training sample sizes than the KNN algorithm, which produced a greater average accuracy across lower training sample sizes. At the largest training sample size of 2500 retinal images, the CNN was over 6% higher in accuracy compared to KNN. This could signify that CNN's accuracy would continue growing at a higher rate with additional training samples. This acknowledgment could prove to be valuable to larger researchers or worldwide resources.

### Statistical Analysis:

The inventors collected a combination of nominal (type of algorithm), type of training sample size, and DR severity (and ratio data, accuracy). Their data examined the relationship between the type of algorithm and accuracy, for different training sample sizes in identifying specific stages of diabetic retinopathy in retinal images. For each type of training sample size, researchers incorporated an independent measures design in which different retinal images were used per trial, and the quantitative variable (accuracy) was measured in reference to two categorical variables (type of algorithm and DR severity). The inventors used an interaction p-value of 0.000249. For a training sample size of 375 retinal images, the ANOVA test generated an interaction p-value of 0.0001786. For a training sample size of 500 retinal images, the ANOVA test generated an interaction p-value of 0.001463. For a training sample size of 1000 retinal images, the ANOVA test generated an interaction p-value of 0.0000272. For a training sample size of 1500 retinal images, the ANOVA test generated an interaction p-value of 0.0000077. For a training sample size of 2000 retinal images, the ANOVA test generated an interaction p-value of 0.00002475. All of the p-values from the ANOVA test were less than the significance level of 0.05, which meant the null hypothesis was rejected. There was no statistical significance between the type of algorithm and its average accuracy across training sample sizes, was rejected. This signifies that there is a statistically significant relationship. In addition to this, the residuals followed a normal distribution as shown by the Q-Q plot. Furthermore, every interaction priori power generated by the ANOVA test was greater than 0.9850, signifying that the results are likely valid.



## MARKET POTENTIAL (4 Ps) & SOCIAL VALUE

### Place:

Our market potential consists of millions of people across the globe suffering vision complications as a result of diabetic retinopathy, seemingly taking the worst. These severe cases are often seen in developing nations where general access to medical testing is bleak with most patients unsure of their severity until physical implications become apparent. In fact, 79% of the adults with diabetes reside within low-to-middle income nations and serve a major risk of joining the estimated 93 million people worldwide suffering from diabetic retinopathy. Without significant medical testing, which can often prove expensive, this population is the most at risk of developing blindness and suffering the consequences of vision impairment.

### Product:

This is where our product comes in: the Visionbound device diagnoses a patient by the severity of diabetic retinopathy in order to combat vision complications early on. VisionBound increases access to diabetic retinopathy testing and diminishes the vision complications that form from diabetic retinopathy.

### Pricing:

At the affordable price of \$250.00 (provided a margin of profit), our product redefines the current market of DR utilities in both its product-line pricing in terms of customization and its pioneer/budget price point that remains extremely competitive amongst peers.

**Distribution:**  
To increase in technology usage, we believe an essential aspect of product promotion is digital marketing and services. With this in mind, Visionbound is featured on our self-designed and developed website, <https://medibound.com>. With this website, we plan to take our product to market very soon.

### Social Value:

We propose that our product, Visionbound, will benefit our target market by diagnosing patients by the severity of diabetic retinopathy in order to combat vision complications early on. To offer context, our target market encompasses millions of people across the globe suffering vision complications as a result of diabetic retinopathy, mostly due to the lack of appropriate testing. Our product offers social value by increasing access to diabetic retinopathy testing and diminishes the vision complications that form from diabetic retinopathy.